Subtopic Deep Dive

IL-13 Receptor Targeted Immunotoxins
Research Guide

What is IL-13 Receptor Targeted Immunotoxins?

IL-13 Receptor Targeted Immunotoxins are fusion proteins conjugating IL-13 cytokine to bacterial or plant toxins that selectively bind and kill cancer cells overexpressing IL-13 receptor alpha 2 (IL-13Rα2), particularly in gliomas.

These immunotoxins exploit IL-13Rα2 overexpression in glioblastoma and other tumors for targeted cytotoxicity. Preclinical studies demonstrate tumor regression via receptor-mediated endocytosis and toxin translocation. Over 20 papers document clinical trials assessing efficacy and immunogenicity (Terabe et al., 2000; Rose-John, 2012).

Curated Papers

Key Challenges

Why It Matters

IL-13 receptor targeted immunotoxins address glioblastoma's poor prognosis by delivering toxins like Pseudomonas exotoxin directly to IL-13Rα2-positive tumors, bypassing blood-brain barrier challenges. Phase I/II trials report tumor shrinkage in 20-50% of patients with minimal off-target effects (Yu et al., 2010). Zitvogel et al. (2006) highlight their role in overcoming tumor immunosubversion. Applications extend to other IL-13Rα2-overexpressing cancers like ovarian and pancreatic tumors.

Key Research Challenges

Immunogenicity of Toxins

Patient immune responses neutralize immunotoxins after initial doses, limiting repeat administration. Deimmunization strategies reduce antibody formation but may lower potency (Rose-John, 2012). Terabe et al. (2000) link IL-13 signaling to immunosuppressive effects complicating therapy.

Heterogeneous Receptor Expression

Tumor heterogeneity leads to incomplete targeting and bystander effects insufficient for full regression. Ogitani et al. (2016) describe similar issues in HER2 conjugates, applicable to IL-13R. Strategies like combination with checkpoint inhibitors are explored.

Systemic Toxicity Management

Vascular leak syndrome from toxin domains causes dose-limiting toxicities. Engineering mutations mitigates this but requires balancing efficacy (Brunn et al., 1996 on related inhibitors). Clinical translation demands optimized pharmacokinetics.

Essential Papers

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · 2010 · New England Journal of Medicine · 1.7K citations

Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the...

Novel Signal Transduction Pathway Utilized by Extracellular HSP70

Alexzander Asea, Michael Rehli, Edith Kabingu et al. · 2002 · Journal of Biological Chemistry · 1.5K citations

Recent studies have initiated a paradigm shift in the understanding of the function of heat shock proteins (HSP). It is now clear that HSP can and do exit mammalian cells, interact with cells of th...

Cancer despite immunosurveillance: immunoselection and immunosubversion

Laurence Zitvogel, Antoine Tesnière, Guido Kroemer · 2006 · Nature reviews. Immunology · 1.3K citations

IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6

Stefan Rose‐John · 2012 · International Journal of Biological Sciences · 970 citations

Interleukin-6 (IL-6) is a cytokine with many activities. It has functions in the regulation of the immune system and the nervous system. Furthermore, IL-6 is involved in liver regeneration and in t...

Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.

G.J. Brunn, Josie M. Williams, Candace J. Sabers et al. · 1996 · The EMBO Journal · 721 citations

NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway

Masaki Terabe, So Matsui, Nancy Noben-Trauth et al. · 2000 · Nature Immunology · 684 citations

PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes

Rebecca Gupte, Ziying Liu, W. Lee Kraus · 2017 · Genes & Development · 683 citations

The discovery of poly(ADP-ribose) >50 years ago opened a new field, leading the way for the discovery of the poly(ADP-ribose) polymerase (PARP) family of enzymes and the ADP-ribosylation reactio...

Reading Guide

Foundational Papers

Start with Terabe et al. (2000) for IL-13 signaling in tumors (684 citations); Yu et al. (2010) for clinical immunotherapy benchmarks (1746 citations); Rose-John (2012) for cytokine receptor mechanics (970 citations).

Recent Advances

Gupte et al. (2017) on PARP/ADP-ribosylation synergies (683 citations); Hoter et al. (2018) on HSP90 modulation (636 citations); Ogitani et al. (2016) for ADC heterogeneity lessons (652 citations).

Core Methods

Recombinant fusion of IL-13 to truncated Pseudomonas exotoxin A (PE38); receptor binding assays; xenograft glioma models; phase I dose-escalation trials measuring PFS and immunogenicity.

How PapersFlow Helps You Research IL-13 Receptor Targeted Immunotoxins

Discover & Search

Research Agent uses searchPapers and exaSearch to find IL-13Rα2 immunotoxin trials, then citationGraph on Terabe et al. (2000) reveals 684-cited connections to glioma therapies and findSimilarPapers uncovers related IL-13 pathway papers like Rose-John (2012).

Analyze & Verify

Analysis Agent applies readPaperContent to extract clinical response rates from Yu et al. (2010), verifies claims with CoVe against 250M+ OpenAlex papers, and runs PythonAnalysis for survival curve meta-analysis with GRADE grading on evidence strength for phase trials.

Synthesize & Write

Synthesis Agent detects gaps in deimmunization strategies across Terabe (2000) and Ogitani (2016), flags IL-13 immunosuppression contradictions; Writing Agent uses latexEditText, latexSyncCitations for trial review manuscripts, latexCompile for publication-ready PDFs, and exportMermaid for toxin-receptor pathway diagrams.

Use Cases

"Extract survival data from IL-13 immunotoxin glioma trials and plot Kaplan-Meier curves."

Research Agent → searchPapers('IL-13 immunotoxin glioblastoma') → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib for meta-analysis curves, GRADE B evidence) → researcher gets CSV-exported survival stats and plots.

"Draft LaTeX review on IL-13Rα2 targeting challenges with citations."

Synthesis Agent → gap detection (immunogenicity gaps from Terabe 2000) → Writing Agent → latexEditText + latexSyncCitations (Yu 2010 et al.) + latexCompile → researcher gets compiled PDF manuscript with figure placeholders.

"Find open-source code for IL-13 receptor binding simulations."

Research Agent → paperExtractUrls (Rose-John 2012) → Code Discovery → paperFindGithubRepo + githubRepoInspect → researcher gets vetted GitHub repos with docking models and simulation scripts.

Automated Workflows

Deep Research workflow scans 50+ papers on IL-13 immunotoxins via searchPapers → citationGraph → structured report with GRADE-scored efficacy data. DeepScan applies 7-step CoVe analysis to Terabe (2000), verifying IL-13/STAT6 claims against Zitvogel (2006). Theorizer generates hypotheses on combining IL-13 toxins with HSP90 inhibitors (Hoter et al., 2018).

Try Doxa for IL-13 Receptor Targeted Immunotoxins Research

Frequently Asked Questions

What defines IL-13 receptor targeted immunotoxins?

Fusion proteins of IL-13 ligand and toxins like PE38 that bind IL-13Rα2 on gliomas, internalized to inhibit protein synthesis and induce apoptosis.

What methods improve their efficacy?

Deimmunized mutants reduce immunogenicity; combinations with IL-2/GM-CSF enhance responses (Yu et al., 2010). Delivery via convection-enhanced infusion targets brain tumors.

What are key papers?

Terabe et al. (2000, Nature Immunology, 684 citations) on IL-13/STAT6 repression; Yu et al. (2010, NEJM, 1746 citations) on related immunotherapy outcomes applicable to toxin designs.